Cargando…

Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer

Brain metastases are a leading cause of death in patients with breast cancer. The lack of clinical trials and the presence of the blood–brain barrier limit therapeutic options. Furthermore, overexpression of the human epidermal growth factor receptor 2 (HER2) increases the incidence of breast cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cordero, Alex, Ramsey, Matthew D., Kanojia, Deepak, Fares, Jawad, Petrosyan, Edgar, Schwartz, Charles W., Burga, Rachel, Zhang, Peng, Rashidi, Aida, Castro, Brandyn, Xiao, Ting, Lee-Chang, Catalina, Miska, Jason, Balyasnikova, Irina V., Ahmed, Atique U., Lesniak, Maciej S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2021
Materias:	Biological Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740706/ https://www.ncbi.nlm.nih.gov/pubmed/34969858 http://dx.doi.org/10.1073/pnas.2112491119

Ejemplares similares

The Network of Cytokines in Brain Metastases
por: Fares, Jawad, et al.
Publicado: (2021)

FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis
por: Cordero, Alex, et al.
Publicado: (2019)

A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model
por: Kim, Julius W., et al.
Publicado: (2017)

The use of anti-GITR antibody treatment in a murine model of glioblastoma multiforme
por: Miska, Jason, et al.
Publicado: (2015)

The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer
por: Sirhan, Zaid, et al.
Publicado: (2022)

STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma
por: Zhang, Peng, et al.
Publicado: (2023)

Polyamines drive myeloid cell survival by buffering intracellular pH to promote immunosuppression in glioblastoma
por: Miska, Jason, et al.
Publicado: (2021)

A novel single-chain antibody redirects adenovirus to IL13Rα2-expressing brain tumors
por: Kim, Julius W., et al.
Publicado: (2015)

Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib
por: Ulrich, Lara, et al.
Publicado: (2021)

Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer
por: Corti, C., et al.
Publicado: (2021)

The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis
por: Antonazzo, Ippazio Cosimo, et al.
Publicado: (2023)

HIF-1α Is a Metabolic Switch between Glycolytic-Driven Migration and Oxidative Phosphorylation-Driven Immunosuppression of Tregs in Glioblastoma
por: Miska, Jason, et al.
Publicado: (2019)

Activation of 4-1BBL(+) B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma
por: Lee-Chang, Catalina, et al.
Publicado: (2020)

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment
por: Topletz-Erickson, Ariel R., et al.
Publicado: (2022)

Effect of Tucatinib on Cardiac Repolarization in Healthy Volunteers
por: Topletz-Erickson, Ariel R., et al.
Publicado: (2023)

Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer
por: Kaufman, Peter A., et al.
Publicado: (2023)

Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma
por: Panek, Wojciech K., et al.
Publicado: (2017)

Intranasal Oncolytic Virotherapy with CXCR4-Enhanced Stem Cells Extends Survival in Mouse Model of Glioma
por: Dey, Mahua, et al.
Publicado: (2016)

HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
por: Olson, Devra, et al.
Publicado: (2023)

Glioma microenvironment-derived CCL2 recruits regulatory T cells and myeloid-derived suppressor cells
por: Chang, Alan L, et al.
Publicado: (2015)

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
por: Lin, Nancy U., et al.
Publicado: (2020)

LMAP-15 INTRACRANIAL RADIOTHERAPY WITH TUCATINIB FOR BRAIN METASTASIS FROM HER2-POSITIVE BREAST CANCER: A SINGLE-INSTITUTION SERIES
por: Khatri, Vaseem, et al.
Publicado: (2023)

The Interplay between Glioblastoma and Its Microenvironment
por: Dapash, Mark, et al.
Publicado: (2021)

53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB)
por: Lin, Nancy, et al.
Publicado: (2020)

Evaluation of Safety and Clinically Relevant Drug–Drug Interactions with Tucatinib in Healthy Volunteers
por: Topletz-Erickson, Ariel, et al.
Publicado: (2022)

Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade
por: Dmello, Crismita, et al.
Publicado: (2023)

Temozolomide Treatment Increases Fatty Acid Uptake in Glioblastoma Stem Cells
por: Caragher, Seamus, et al.
Publicado: (2020)

Neural Stem Cell Carriers for the Treatment of Glioblastoma Multiforme
por: Miska, Jason, et al.
Publicado: (2015)

Fatty Acid Uptake in T Cell Subsets Using a Quantum Dot Fatty Acid Conjugate
por: Muroski, Megan E., et al.
Publicado: (2017)

Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects
por: Topletz‐Erickson, Ariel R., et al.
Publicado: (2020)

Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC–MS/MS assay
por: Zhang, Ying, et al.
Publicado: (2022)

Low-level whole-brain radiation enhances theranostic potential of single-domain antibody fragments for human epidermal growth factor receptor type 2 (HER2)-positive brain metastases
por: Procissi, Daniele, et al.
Publicado: (2022)

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial
por: Lin, Nancy U., et al.
Publicado: (2022)

Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters
por: Kim, Julius Woongki, et al.
Publicado: (2016)

Modelling the structural and reactivity landscapes of tucatinib with special reference to its wavefunction-dependent properties and screening for potential antiviral activity
por: Alsalme, Ali, et al.
Publicado: (2020)

Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice
por: Auffinger, Brenda, et al.
Publicado: (2013)

Mesenchymal Stem Cells Modified with a Single-Chain Antibody against EGFRvIII Successfully Inhibit the Growth of Human Xenograft Malignant Glioma
por: Balyasnikova, Irina V., et al.
Publicado: (2010)

In vitro and ex vivo anti-tumor effect and mechanism of Tucatinib in leukemia stem cells and ABCG2-overexpressing leukemia cells
por: Jing, Wen, et al.
Publicado: (2021)

IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM
por: Zannikou, Markella, et al.
Publicado: (2023)

Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives
por: Wu, Qiuji, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_if2vldmeo5k058d17esc1e5s3o